Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
281 daily bars · split adjusted
Daily · Wilder smoothing
Annual filings (FY) with consensus forward estimates (hatched)
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 54.66 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 59.98 | Oscillator | Neutral |
| Williams %R (14) | -42.86 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.01 (Hist 0.01) | Oscillator | Strong Buy |
| Average Directional Index (14) | 25.91 (+DI 22.2 / -DI 17.4) | Trend | Strong Buy |
| EMA 20 | 0.92 | MA | Strong Buy |
| SMA 20 | 0.90 | MA | Strong Buy |
| EMA 50 | 0.91 | MA | Strong Buy |
| SMA 50 | 0.90 | MA | Strong Buy |
| SMA 200 | 0.98 | MA | Sell |
Current price $0.96
Latest analyst grade actions
TTM vs. 5-year historical average (annual ratios)
| Metric | BGMS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.3x | -0.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.0x | EPS est. -268.80 | Discount |
| Price / Book | 0.8x | 0.1x | Elevated |
| Price / Sales | 2.8x | 1.9x | Elevated |
| EV / EBITDA | -0.6x | 0.5x | Discount |
| Return on equity | -31.6% | — | Weak |
| Gross margin | 19.3% | 43.7% | Below hist. |
| Debt / Equity | 0.00 | 0.01 | Conservative |
| Piotroski / Altman Z | 4/9 | Z -76.63 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Nov 12, 25 | Kiu Cu Seng | director, officer: Chief Financial Officer | A-Award | 200,000 @ $1.40 | $280.0K |
| Nov 12, 25 | Doris Wong Sing Ee | director, 10 percent owner, officer: Chief Executive Officer | A-Award | 300,178 @ $1.40 | $420.2K |
| Nov 5, 25 | Yap Kim Choy | 10 percent owner | J-Other | 467,535 | — |
| Nov 5, 25 | Yap Kim Choy | 10 percent owner | J-Other | 218,000 @ $7.65 | $1.67M |
| Nov 5, 25 | Yap Kim Choy | 10 percent owner | J-Other | 218,000 @ $9.00 | $1.96M |
| Nov 5, 25 | Yap Kim Choy | 10 percent owner | J-Other | 31,535 @ $10.20 | $321.7K |
| Nov 5, 25 | Yap Kim Choy | 10 percent owner | S-Sale | 28,540 @ $1.70 | $48.52K |
| Nov 5, 25 | Ong Yee Lung | 10 percent owner | J-Other | 467,535 | — |
Stock news · updated daily
EquipmentShare.com (NASDAQ: EQPT - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Profitability This table compares EquipmentShare.com and Cyclacel Pharmaceuticals' net
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:
Cyclacel Pharmaceuticals, Inc. (NASDAQ: BGMS - Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 90,785 shares, a growth of 160.2% from the August 31st total of 34,897 shares. Currently, 2.2% of the shares of the stock are short sold. Based
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced second quarter financial results and provided a business update.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Profitability This table compares Cyclacel Pharmaceuticals and
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | — | -0.08 | — | $336.0K |
| May 14, 2026 | — | -0.04 | — | $778.0K |
| Mar 30, 2026 | -72.00 | -2.21 | Beat 96.9% | $666.0K |
| Nov 13, 2025 | -72.00 | -1.31 | Beat 98.2% | $81.00K |
| Aug 13, 2025 | -72.00 | -0.98 | Beat 98.6% | — |
| May 15, 2025 | -69.60 | -0.09 | Beat 99.9% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| S-3 | Oct 23, 2026 | 2026-10-23 16:05:32 | View |
Proxy statement (DEF 14A) disclosures